Matthew Castelo1,2, Justin Lu3, Lawrence Paszat2,4, Zachary Veitch5, Kuan Liu2, Adena S Scheer6,7,8. 1. Division of General Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada. 2. Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. 3. Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 4. Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada. 5. Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada. 6. Division of General Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada. adena.scheer@unityhealth.to. 7. Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. adena.scheer@unityhealth.to. 8. Division of General Surgery, St. Michael's Hospital, 3-005 Donnelly Wing, 30 Bond St, Toronto, ON, M5B 1W8, Canada. adena.scheer@unityhealth.to.
Abstract
BACKGROUND: Older women are poorly represented in trials evaluating chemotherapy for breast cancer (BC). This study aimed to describe survival and associated factors among elderly women receiving chemotherapy for non-metastatic BC. METHODS: This was a population-based cohort study including women ≥ 70 years old diagnosed with invasive, non-metastatic BC from 2010 to 2017 in SEER. Among those who received chemotherapy, overall survival (OS) was determined using Kaplan-Meier curves and hazard ratios were reported with 95% confidence intervals (CIs). Adjustment was made for available confounders. Co-morbidity is not available in SEER. BC-specific survival (BCSS) and subdistribution hazard ratios were determined using competing risks analysis. RESULTS: The cohort consisted of 109,239 women aged 70+, of whom 17,961 (16%) received chemotherapy. Chemotherapy patients were younger (median 73.0 years vs. 77.0), had more advanced disease (25% stage III vs. 5.2%), and were more likely to receive mastectomy (50% vs. 33%). Among chemotherapy patients, 5-year OS was 77.8% (95% CI 76.9-78.6%), and for women 80+ was 60.2% (95% CI 57.5-63.1%). More recent diagnoses, no previous history of cancer, and receipt of radiotherapy were all associated with improved BCSS. Conversely, older age, higher tumour grade, advanced stage, and human epidermal growth factors receptor (HER)2 negative tumours were associated with worse BCSS. 56% of deaths were due to BC, and women aged 80+ had worse BCSS compared to those aged 70-79 (adjusted sdHR 1.62, 95% CI 1.43-1.84). CONCLUSIONS: Elderly women with advanced disease can achieve good survival after chemotherapy for non-metastatic BC. Those with HER2+ disease have superior survival, reinforcing benefit in this population.
BACKGROUND: Older women are poorly represented in trials evaluating chemotherapy for breast cancer (BC). This study aimed to describe survival and associated factors among elderly women receiving chemotherapy for non-metastatic BC. METHODS: This was a population-based cohort study including women ≥ 70 years old diagnosed with invasive, non-metastatic BC from 2010 to 2017 in SEER. Among those who received chemotherapy, overall survival (OS) was determined using Kaplan-Meier curves and hazard ratios were reported with 95% confidence intervals (CIs). Adjustment was made for available confounders. Co-morbidity is not available in SEER. BC-specific survival (BCSS) and subdistribution hazard ratios were determined using competing risks analysis. RESULTS: The cohort consisted of 109,239 women aged 70+, of whom 17,961 (16%) received chemotherapy. Chemotherapy patients were younger (median 73.0 years vs. 77.0), had more advanced disease (25% stage III vs. 5.2%), and were more likely to receive mastectomy (50% vs. 33%). Among chemotherapy patients, 5-year OS was 77.8% (95% CI 76.9-78.6%), and for women 80+ was 60.2% (95% CI 57.5-63.1%). More recent diagnoses, no previous history of cancer, and receipt of radiotherapy were all associated with improved BCSS. Conversely, older age, higher tumour grade, advanced stage, and human epidermal growth factors receptor (HER)2 negative tumours were associated with worse BCSS. 56% of deaths were due to BC, and women aged 80+ had worse BCSS compared to those aged 70-79 (adjusted sdHR 1.62, 95% CI 1.43-1.84). CONCLUSIONS: Elderly women with advanced disease can achieve good survival after chemotherapy for non-metastatic BC. Those with HER2+ disease have superior survival, reinforcing benefit in this population.
Authors: François Lagacé; Feras M Ghazawi; Michelle Le; Elham Rahme; Evgeny Savin; Andrei Zubarev; Akram Alakel; Denis Sasseville; Linda Moreau; Sarkis Meterissian; Ivan V Litvinov Journal: Breast Cancer Res Treat Date: 2019-09-04 Impact factor: 4.872
Authors: Hyman B Muss; Mei-Yin C Polley; Donald A Berry; Heshan Liu; Constance T Cirrincione; Maria Theodoulou; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn G Dressler; Harvey J Cohen; Patricia A Kartcheske; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Linda M Sutton; Gustav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Arti Hurria; Aminah Jatoi; Larry Norton; Clifford A Hudis; Eric P Winer; Lisa Carey Journal: J Clin Oncol Date: 2019-07-24 Impact factor: 44.544
Authors: Jennifer A Crozier; Todd A Pezzi; Caitlin Hodge; Slavica Janeva; Beth-Ann Lesnikoski; Laila Samiian; Amanda Devereaux; William Hammond; Riccardo A Audisio; Christopher M Pezzi Journal: Lancet Oncol Date: 2020-12 Impact factor: 41.316
Authors: Ajeet Gajra; Linda McCall; Hyman B Muss; Harvey J Cohen; Aminah Jatoi; Karla V Ballman; Ann H Partridge; Linda Sutton; Barbara A Parker; Gustav Magrinat; Heidi D Klepin; Jacqueline M Lafky; Arti Hurria Journal: J Geriatr Oncol Date: 2018-03-28 Impact factor: 3.599
Authors: Jeanne S Mandelblatt; Ling Cai; George Luta; Gretchen Kimmick; Jonathan Clapp; Claudine Isaacs; Brandeyln Pitcher; William Barry; Eric Winer; Stephen Sugarman; Clifford Hudis; Hyman Muss; Harvey J Cohen; Arti Hurria Journal: Breast Cancer Res Treat Date: 2017-03-31 Impact factor: 4.872